http://www.fiercebiotech.com/press-releases/medarex-receive-milestone-payment-approval-simponi-tm-treatment-rheumatoid-arthriti-0
"PRINCETON, N.J., April 14 /PRNewswire-FirstCall/ -- Medarex, Inc.
(NASDAQ: MEDX) today announced that it will receive a milestone payment
of an undisclosed amount from its licensing partner, Centocor Ortho
Biotech Inc., in connection with the marketing approval from Health
Canada's Biologics and Genetic Therapies Directorate, to market
SIMPONI(TM) (golimumab, also known as CNTO 148) as a once-monthly
subcutaneous treatment for adults with active forms of rheumatoid
arthritis, psoriatic arthritis and ankylosing spondylitis."
thanks for the info!
Copyright ArthritisInsight.com